Stockreport

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3ß Inhibitor

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential to Activa [Read more]